Anticoagulation may be beneficial in high risk factor V Leiden carriers

BMJ 1998;317:416 ( 8 August )

Letters

Anticoagulation may be beneficial in high risk factor V Leiden carriers

The first 150 words of the full text of this article appear below.

EDITOR $---$ Sarasin and Bounameaux's decision analysis model of treatment in factor V Leiden carriers¹ is in keeping with the results of our cohort study.² In our study the annual rate of recurrence when treatment with warfarin was stopped was 11.1per 100 patient-years. Patients who had an idiopathic first eventwere more likely to have a recurrence than those whose first eventwas precipitated (log rank=4.76, P=0.029). The recurrence ratein these high risk patients was 28.6 per 100 patient-years.

In a previous prospective cohort study of patients who had had a first deep vein thrombosis 11.5% of recurrent events werefatal, but all deaths occurred in patients with cancer.³ Inthe absence of cancer the risk of fatal recurrence was zero aftera median follow up of nearly eight years. Even if 1% of eventsare assumed to be fatal in the absence of cancer, our study indicatesthat the risks . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Article

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis: François P Sarasin and Henri Bounameaux
BMJ 1998 316: 95-99. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

Connor, J. A. (2005). Factor V Leiden and Its Effect on Children With Cardiac Pathology. Journal of Pediatric Oncology Nursing 22: 176-181 [Abstract]